Scalper1 News
Big biotech Celgene (CELG) announced Monday that it will present data on its Crohn’s disease drug GED-0301 at a conference Tuesday, after posting an abstract with top-line results on the high side of expectations. Celgene stock was up 2.5% in morning trading on the stock market today. The drug is a potential blockbuster. The phase-two trial compared three different doses of the drug, also called Mongersen, with a group taking a placebo. After two Scalper1 News
Scalper1 News